EPCR基因敲除:引发炎症讨论
本文评述Magisetty等在《Blood》发表的研究,该研究探讨内皮蛋白C受体(EPCR)在血友病关节病中的作用;基于EPCR促进蛋白C活化及FVIIa结合EPCR增强止血的既往证据,新研究结果出人意料。
要点
- EPCR促进蛋白C活化为活化蛋白C,后者通过灭活FVa发挥抗血栓作用。
- 活化的凝血因子VIIa也可结合EPCR,该结合在血友病小鼠模型中增强止血效应。
- EPCR阻断本身未减轻血友病小鼠出血严重程度,aPC生成下调被认为是FVIIa经EPCR发挥止血效应的主要机制。
核心结论
- Magisetty等关于EPCR在血友病关节病中作用的研究结果出人意料。
研究设计与样本
- 本文为对Magisetty等在《Blood》发表研究的评论文章。
主要发现
- EPCR在内皮表面促进蛋白C活化为活化蛋白C,活化蛋白C通过灭活邻近内皮表面的FVa发挥抗血栓效应。
- 活化的凝血因子VIIa也可结合EPCR;Pavani等在小鼠血友病模型中以氯化铁诱导血栓形成检测,显示结合EPCR增强FVIIa的止血效应。
- Rao团队显示止血水平的FVIIa可将蛋白C从EPCR置换,在隐静脉出血试验中阻断EPCR可降低止血所需FVIIa水平。
- Rao团队报告EPCR阻断本身未降低血友病小鼠出血严重程度,并结论aPC生成下调是FVIIa与EPCR相互作用贡献血友病中FVIIa止血效应的主要机制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this issue of Blood, Magisetty et al provide some surprising results from their studies of the role of endothelial protein C receptor (EPCR) in hemophilic arthropathy. There is a rationale for studying EPCR in hemophilia. It is well recognized that EPCR promotes the activation of protein C (PC) to activated PC (aPC) on endothelial surfaces. The aPC has antithrombotic effects by inactivating factor Va (FVa) on nearby endothelial surfaces. Like aPC, activated coagulation FVIIa can also bind to EPCR. Pavani et al showed that binding to EPCR enhances the hemostatic effect of FVIIa in a mouse hemophilia model, when assayed as ferric chloride–induced thrombosis. The Rao group showed that hemostatic levels of FVIIa displace PC from EPCR, and blockade of EPCR reduces the level of FVIIa needed for hemostasis in a saphenous vein bleeding assay. However, they reported that EPCR blockade by itself did not reduce the severity of bleeding in hemophilic mice. They concluded that downregulation of aPC generation is the major mechanism by which FVIIa interaction with EPCR contributes to the hemostatic effect of FVIIa in hemophilia.
引用
- Monroe D, Hoffman M. EPCR knockout: inflaming the discussion. Blood. 2020. PMID: 32556134. doi:10.1182/blood.2020006001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。